• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Oncology

Adjuvant erlotinib increased overall survival when compared to chemotherapy in stage IIIA EGFR-mutant non-small cell lung cancer

byJohan PushaniandSze Wah Samuel Chan
September 5, 2022
in Chronic Disease, Oncology, Pulmonology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Erlotinib showed an overall survival benefit and improved 5-year survival rates when compared to chemotherapy.

2. Disease-free survival was significantly better in the erlotinib arm than with chemotherapy in the intention-to-treat population and per-protocol populations.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Patients with non-small cell lung cancer (NSCLC) who undergo complete resection tend to frequently have disease recurrence despite recent improvements in cancer therapy. A previous study (EVAN) explored the use of erlotinib (an epidermal growth factor receptor tyrosine kinase inhibitor [EGFR-TKI]) versus vinorelbine/cisplatin as adjuvant chemotherapy options after complete resection in patients with stage III EGFR-mutant NSCLC. This study describes the updated results of the EVAN study. Updated disease-free survival (DFS) data was obtained and the DFS was significantly better with erlotinib than with chemotherapy in the intention-to-treat (ITT) and per-protocol populations. Median overall survival (OS) and 5-year survival rates were significantly higher in the erlotinib arm. Whole-exome sequencing (WES) was performed and while one single-nucleotide polymorphism (SNP) mutation was found to be associated with significantly worse DFS in the erlotinib-arm, there was no statistical association with OS and DFS. Limitations to this study include its generalizability due to its solely Chinese population and advanced disease stage population, which yields no information on treatment benefits to earlier disease stages. The strength of this study is that it expanded upon its previous report and that it showed an OS benefit in NSCLC patients who typically experience modest survival rates. Overall, erlotinib is a promising option for patients with R0 resection stage III EGFR-mutant NSCLC.

Click to read the study in the JCO

Relevant Reading: Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer

In-Depth [randomized control trial]: This phase II trial included 102 patients with stage IIIA EGFR-mutant NSCLC who underwent complete resection. Patients were randomly assigned in a 1:1 ratio to receive erlotinib or vinorelbine plus cisplatin as adjuvant chemotherapy; 51 patients were in each arm. Median follow-up was 54.8 months and 63.9 months in the erlotinib and chemotherapy arms, respectively, with updated results at the 43-month follow-up. In the erlotinib arm, 5-year DFS in the ITT population was 48.2% (95% confidence interval [CI], 29.4 to 64.7) and 46.2% (95% CI, 27.6 to 62.9) in the per-protocol population. 5-year DFS for the chemotherapy arm could not be calculated due to either the endpoint being reached or the patients being censored at the end of follow-up. DFS was statistically better with erlotinib in the ITT population (hazard ratio [HR], 0.38; 95% CI, 0.20 to 0.70; P<0.001) and in the per-protocol population (HR, 0.46; 95% CI, 0.24 to 0.88; P=0.008). Median OS was 84.2 months (95% CI, 78.1 to not evaluable) and 61.1 months (95% CI, 39.6 to 82.1) with erlotinib and chemotherapy, respectively (HR, 0.318; 95% CI, 0.151 to 0.670). 5-year survival rates were 84.8% (95% CI, 72.0 to 97.6) and 51.1% (95% CI, 34.7 to 67.5), respectively. WES found the SNP mutation UBXN11 in the erlotinib-treated patients to be associated with significantly worse DFS (P=0.01), but there was no association with OS and DFS. Overall, erlotinib showed an overall survival benefit in stage IIIA EGFR-mutant NSCLC patients.

RELATED REPORTS

#VisualAbstract: Continuation of renin–angiotensin system inhibitors does not impact disease progression in those with advanced chronic kidney disease

SGLT2 inhibitors reduce the risk of kidney disease in patients with and without diabetes

#VisualAbstract: Induction chemotherapy with erlotinib does not improve survival in stage III-IV head and neck squamous cell carcinoma

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: early stage lung cancereGFRErlotinib
Previous Post

Dolutegravir associated with improved viral suppression in HIV-positive pregnant patients

Next Post

Sacituzumab govitecan may be an effective treatment for heavily pre-treated HR+/HER2- metastatic breast cancer.

RelatedReports

#VisualAbstract: Continuation of renin–angiotensin system inhibitors does not impact disease progression in those with advanced chronic kidney disease
StudyGraphics

#VisualAbstract: Continuation of renin–angiotensin system inhibitors does not impact disease progression in those with advanced chronic kidney disease

December 6, 2022
Tenofovir disoprovil fumarate HIV prophylaxis linked with minimal kidney impact
Chronic Disease

SGLT2 inhibitors reduce the risk of kidney disease in patients with and without diabetes

November 30, 2022
#VisualAbstract: Induction chemotherapy with erlotinib does not improve survival in stage III-IV head and neck squamous cell carcinoma
StudyGraphics

#VisualAbstract: Induction chemotherapy with erlotinib does not improve survival in stage III-IV head and neck squamous cell carcinoma

September 27, 2022
Significant reduction in prostate screening rates after revised guidelines
Chronic Disease

Discrepancies exist between measured and estimated glomerular filtration rate

July 18, 2022
Next Post
Age and number of islet autoantibodies associated with diabetes risk

Sacituzumab govitecan may be an effective treatment for heavily pre-treated HR+/HER2- metastatic breast cancer.

Patient Basics: Heart Attack (Myocardial Infarction)

Ischemic events associated with greater mortality risk than bleeding events among adults with acute myocardial infarction on antithrombotic therapy

Physical function as a predictor for cardiovascular disease risk in the elderly

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Higher body mass index may be associated with altered vitamin D levels and metabolism
  • #VisualAbstract: Torsemide does not provide additional decrease in mortality compared to furosemide among patients hospitalized for heart failure
  • Community-based adult vision screening program increases access to eye care
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options